#1
#1 out of 1
health12h ago
Cheap transplant drug delays type 1 diabetes progression
- ATG at the lowest dose preserved beta-cell function for a year in young patients diagnosed within nine weeks.
- Low-dose ATG produced fewer side effects than higher doses, including lower rates of serum sickness.
- ATG is inexpensive and widely available, making it a notable option among treatments delaying type 1 diabetes progression.
- The study included 117 participants aged 5 to 25 diagnosed within nine weeks of starting the trial.
- Researchers dropped the intermediate ATG dose after reviewing side effects across groups.
- The honeymoon phase of type 1 diabetes provides a window to preserve insulin-producing cells longer.
- ATG is one of several drugs under study to delay diabetes progression, alongside teplizumab and baricitinib.
- The study suggests potential for broader use if ATG gains regulatory approval for diabetes.
- Researchers plan future trials with next-generation ATG to improve safety and efficacy.
Vote 0